PT-141
In stockBremelanotideBremelanotide, a cyclic heptapeptide melanocortin receptor agonist that differs from melanotan II at the C-terminus (free acid, not amide). Researchers study melanocortin receptor structure and medicinal chemistry.
Supplied as a single-chamber lyophilized vial with a colour-coded cap (Hormone & Libido).
Research literature, not dosing or treatment instructions.
- Cryo-EM structures of full-length human MC4R were solved with alpha-MSH, afamelanotide, bremelanotide and a small-molecule ligand bound. (PMID 34433901)
- A review covers melanocortin receptor ligands beyond melanocyte-stimulating hormones and ACTH. (PMID 36291616)
- A medicinal-chemistry paper designs mid-size macrocycles for selective melanocortin-receptor targeting, with bremelanotide and setmelanotide as reference macrocycles. (PMID 42340853)
Add the solvent slowly along the vial wall; swirl gently, never shake. Allow to dissolve fully. Six-step guide with photos →
Concentration calculator only. Enter the mass being calculated; blend components are not added automatically. Products are for in-vitro research.
Refer to the product label and supplier documentation for storage conditions. Lot-specific storage and expiry information is not available here.
Each certificate is published with its lot number.
Questions about PT-141
How much published research is there on PT-141?
The research library's PubMed search for PT-141 returned 114 records on 5 October 2026, 56 of them reviews. The library lists 4 studies chosen for what they measured. ClinicalTrials.gov lists 10 registered studies naming PT-141, 6 of them sponsored by Palatin Technologies, Inc (checked 5 October 2026).
Is PT-141 an approved medicine?
Medicinal products containing PT-141 appear in Drugs@FDA, and the research material we supply is not one of them. Drugs@FDA lists 1 application naming this active ingredient, marketing status as listed: Prescription (checked 5 October 2026). Those are medicinal products. The research material we supply is not one of them. It is supplied for in-vitro laboratory research only, not for human or veterinary use.
Is PT-141 the same as bremelanotide?
Yes. PT-141 is also called bremelanotide, the cyclic heptapeptide Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH.
How does PT-141 differ from Melanotan II?
PT-141 and melanotan II are cyclic heptapeptide melanocortin receptor agonists with the same lactam-bridged core. They differ at the C-terminus: PT-141 ends in a free acid and melanotan II in an amide.
How is the identity of PT-141 confirmed on a certificate?
A research-grade certificate of analysis typically reports identity by mass spectrometry and purity by HPLC. The mass result is read against the average molecular weight of 1025.2 Da listed on this page. The research library's guide to reading a certificate explains each field.
What other names is PT-141 published under?
PT-141 is also written Bremelanotide and PT 141. The catalog lists it under the name PT-141.
Is this product for human use?
No. Peptency products are supplied for in-vitro research only. Not for human or veterinary use, not for diagnosis or therapy.
Where can I find shipping information?
Current shipping rates and delivery information are on the Shipping & payment page, and the rates that apply to your order are shown at checkout.
Often studied with
For research use only. Not for human or veterinary use.
What is PT-141?
PT-141, also called bremelanotide, is the cyclic heptapeptide Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, a melanocortin receptor agonist that differs from melanotan II at the C-terminus (free acid rather than amide). Published work covers receptor structure, medicinal chemistry and analytical characterisation. We supply PT-141 as a lyophilized vial for in-vitro laboratory research only.
What are the chemical identifiers of PT-141?
PT-141 has the molecular formula C50H68N14O10, an average molecular weight of 1025.2 Da and CAS number 189691-06-3.
Chemistry checked against PubChem (CID 9941379), 5 October 2026; full chemistry record in the research library.
What does published research on PT-141 cover?
A PubMed search for PT-141 returned 114 records on 5 October 2026, 56 of them reviews. Our research library lists 4 of these studies, chosen for what they measured.
- Cryo-EM structures of full-length human MC4R were solved with alpha-MSH, afamelanotide, bremelanotide and a small-molecule ligand bound. (Zhang et al., Cell Res, 2021; PMID 34433901)
- A review covers melanocortin receptor ligands beyond melanocyte-stimulating hormones and ACTH. (Yuan et al., Biomolecules, 2022; PMID 36291616)
- A medicinal-chemistry paper designs mid-size macrocycles for selective melanocortin-receptor targeting, with bremelanotide and setmelanotide as reference macrocycles. (Merlino et al., J Med Chem, 2026; PMID 42340853)
Mechanism, every cited study and the regulator records are on the PT-141 page of the research library. Papers are listed by what they measured, not as evidence of any use.
How is PT-141 supplied and stored?
PT-141 is supplied as a lyophilized (freeze-dried) powder in a sealed vial, for in-vitro laboratory research only. Our stated storage condition for the sealed lyophilized vial is 2 to 8 °C. The label and the lot certificate carry the lot-specific storage condition and expiry date.
What is the regulatory status of PT-141?
Drugs@FDA lists 1 application naming this active ingredient, marketing status as listed: Prescription (checked 5 October 2026). Those are medicinal products. The research material we supply is not one of them.
A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Which related research pages and compounds are listed?
- PT-141: chemistry, literature and regulatory status
- PT-141 compared with Melanotan II
- Melanocortin receptors
- How to read a certificate of analysis
Related compounds in the catalog: